Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR by Panousis, C et al.
Engineering and characterisation of chimeric monoclonal antibody
806 (ch806) for targeted immunotherapy of tumours expressing
de2-7 EGFR or amplified EGFR
C Panousis
1,4, VM Rayzman
1,4, TG Johns
1, C Renner
1, Z Liu
1, G Cartwright
1, F-T Lee
1, D Wang
1, H Gan
1,
D Cao
1, A Kypridis
1, FE Smyth
1, MW Brechbiel
2, AW Burgess
1, LJ Old
3 and AM Scott*,1
1Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Level 1, Harold Stokes Building, Austin Hospital, 145-163 Studley Road,
Heidelberg 3084. Victoria, Australia;
2Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute. Bethesda, MD
20892, USA;
3Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Centre, New York, NY 10021, USA
We report the generation of a chimeric monoclonal antibody (ch806) with specificity for an epitope on the epidermal growth factor
receptor (EGFR) that is different from that targeted by all other anti-EGFR therapies. Ch806 antibody is reactive to both de2-7 and
overexpressed wild-type (wt) EGFR but not native EGFR expressed in normal tissues at physiological levels. Ch806 was stably
expressed in CHO (DHFR  / ) cells and purified for subsequent characterisation and validated for use in preliminary
immunotherapy investigations. Ch806 retained the antigen binding specificity and affinity of the murine parental antibody.
Furthermore, ch806 displayed enhanced antibody-dependent cellular cytotoxicity against target cells expressing the 806 antigen in
the presence of human effector cells. Ch806 was successfully radiolabelled with both iodine-125 and indium-111 without loss of
antigen binding affinity or specificity. The radioimmunoconjugates were stable in the presence of human serum at 371C for up to 9
days and displayed a terminal half-life (T1/2b) of approximately 78h in nude mice. Biodistribution studies undertaken in BALB/c nude
mice bearing de2-7 EGFR-expressing or amplified EGFR-expressing xenografts revealed that
125I-labelled ch806 failed to display any
significant tumour retention. However, specific and prolonged tumour localisation of’
111In-labelled ch806 was demonstrated with
uptake of 31%IDg
 1 and a tumour to blood ratio of 5:1 observed at 7 days postinjection. In vivo therapy studies with ch806
demonstrated significant antitumour effects on established de2-7 EGFR xenografts in BALB/c nude mice compared to control, and
both murine 806 and the anti-EGFR 528 antibodies. These results support a potential therapeutic role of ch806 in the treatment of
suitable EGFR-expressing tumours, and warrants further investigation of the potential of ch806 as a therapeutic agent.
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Overexpression of the epidermal growth factor receptor (EGFR)
has been observed in many tumours including the breast, lung,
colon, prostate, head and neck, and brain, and increased EGFR
expression frequently correlates with more aggressive clinical
course (Nicholson et al, 2001; Arteaga, 2002; Mendelsohn, 2002).
This overexpression of the receptor is commonly the result of the
EGFR gene amplification (Hendler and Ozanne, 1984; Sainsbury
et al, 1987; Salomon et al, 1995). EGFR gene amplification and
subsequent overexpression of the EGFR protein is particularly
prevalent in gliomas, the most common primary tumour of the
central nervous system (Wikstrand et al, 1997). Indeed, the highly
malignant glioblastoma multiforme exhibits EGFR gene amplifica-
tion at a frequency of 40–50%, with many tumours also exhibiting
structural rearrangements of the EGFR (Voldborg et al, 1997). The
most common of these variant EGFR genes contains an in-frame
801bp deletion that removes exons 2–7 of the EGFR gene (Sugawa
et al, 1990; Wong et al, 1992; Frederick et al, 2000). This resulting
receptor, known as the de2-7 EGFR, does not bind ligand but
displays a low level of constitutive activity and imparts a
significant in vivo growth advantage to a number of tumour types
including the breast, lung and particularly gliomas (Nishikawa
et al, 1994; Wikstrand et al, 1998; Tang et al, 2000).
Because the EGFR is overexpressed in many types of cancer, and
its blockade often inhibits tumour growth, this receptor is a
rational target for novel cancer therapeutics. Potential anti-EGFR
therapeutics include anti-EGFR antibodies (Sato et al, 1987),
EGFR-ligand conjugates, EGFR immunoconjugates, small molecu-
lar weight tyrosine kinase inhibitors (Fry et al, 1994; Levitzki and
Gazit, 1995), dominant-negative EGFR constructs, antisense EGFR
oligonucleotides, all of which are capable of blocking EGFR
function (de Bono and Rowinsky, 2002; Herbst and Langer, 2002;
Herbst and Shin, 2002; Wakeling, 2002).
A number of antibodies directed to the extracellular domain of
the EGFR have been tested in the clinic including EMD 55900 (Bier
et al, 2001), ABX-EGF (Yang et al, 2001) and IMC-C225
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s(Mendelsohn, 1997) with some antitumour activity shown in
patients. The most clinically advanced of these is IMC-225, that is
currently in Phase II/III clinical trials and has recently been
approved by the FDA for use in conjunction with irinotecan in
patients with irinotecan refractory colorectal cancer (Stragliotto
et al, 1996; Herbst and Langer, 2002; Lynch and Yang, 2002).
Significant uptake in normal tissue such as the liver and skin is
a potential limitation of antibodies targeting the wild-type (wt)
EGFR (Divgi et al, 1991; Busam et al, 2001). While targeting of
normal tissue usually produces manageable side effects such as
skin rash, it does mean these antibodies are inappropriate for
coupling with cytotoxic agents or radioisotopes.
Several antibodies have also been developed that specifically
target the tumour-specific de2-7 EGFR (Humphrey et al, 1990;
Hills et al, 1995; Wikstrand et al, 1995). These antibodies are
directed to the unique junctional peptide formed by the deletion
event in the de2-7 EGFR and therefore are specific for this receptor
and do not bind the wt EGFR. We recently described a novel
monoclonal antibody (mAb 806) generated by immunising mice
with cells expressing the full-length de2-7 EGFR (Luwor et al, 2001;
Mishima et al, 2001; Johns et al, 2002; Jungbluth et al, 2003).
Scatchard analysis demonstrated mAb 806 binds only approxi-
mately 10% of the wt EGFR on the surface of A431 cells, a cell line
that over-expresses the wt EGFR (Johns et al, 2002). In the absence
of ligand, the majority of wt EGFR on the cell surface is in an
inactive or ‘tethered’ form. In order to form active dimers, the
EGFR untethers and undergoes a conformational change. The mAb
806 epitope is only exposed when the receptor is in this transient
state between inactive and active dimer (Johns et al, 2004). Thus, at
any given time point, mAb 806 can only bind this small fraction of
EGFR in the correct conformation. Interestingly, untethering
appears to occur at an increased rate in cells overexpressing
EGFR, possibly due to changes in glycosylation (Johns et al, 2004).
The extracellular deletion associated with the de2-7 EGFR appears
to expose the mAb 806 epitope allowing constitutive binding of the
antibody. The epitope is different from that targeted by all other
anti-EGFR therapies and is not accessible in normal human tissues
(Jungbluth et al, 2003). Studies with mAb 806 in nude mice have
shown significant antitumour activity against xenografts expres-
sing de2-7 EGFR or amplified EGFR, independent of antibody
effector function (Johns et al, 2002, 2003). Given the unusual
specificity profile and direct antitumour activity, we undertook to
develop this anti-EGFR antibody as a construct with minimal
immunogenicity for potential use in clinical trials. Herein we
describe the construction and subsequent in vitro and in vivo
characterisation of a chimeric mouse–human IgGl construct of
mAb 806 (ch806).
MATERIALS AND METHODS
Antibodies and cell lines
The murine mAb 806 was generated following the immunisation of
mice with NR6 mouse fibroblasts expressing the de2-7 EGFR
(Jungbluth et al, 2003). The 528 antibody, which recognises both
de2-7 and wt EGFR, has been previously described (Luwor et al,
2001).
The dihydrofolate reductase (DHFR)-deficient CHO cell line
DG44 was obtained from Kyowa Hakko Kogyo Co. Ltd, Japan, with
the permission of Professor Chasin, Columbia University, USA
(Morris et al, 1990). These CHO cells were cultured in IMDM
supplemented with 10% fetal calf serum (FCS, CSL Ltd, Parkville,
Victoria, Australia) and hypoxanthine–thymidine (Invitrogen Life
Technologies, Melbourne, Victoria, Australia).
The human glioblastoma cell line U87MG, expressing the wt
EGFR endogenously, and the transfected cell lines U87MG.de2-7,
U87MG.wtEGFR expressing the de2-7 EGFR and overexpressing
the wt EGFR, respectively, have been described previously
(Nishikawa et al, 1994; Nagane et al, 1996). The human epidermoid
carcinoma-derived cell line (A431) has also been described (Sato
et al, 1987). U87MG cell lines and A431 cells were cultured as
previously described (Luwor et al, 2001). A431 cells express 2 10
6
EGFR/cell through amplification of EGFR gene. The 806 antibody
is capable of binding only approximately 10% of the EGFR present
on the A431 cell surface (Johns et al, 2002). The FaDu (HTB-43)
squamous cell carcinoma was obtained from ATCC (Manassas,
VA, USA). This cell line displays normal cell expression levels of
EGFR (2 10
5 EGFR/cell). FaDu cells were maintained in DMEM
(DMEM/F12; Invitrogen Life Technologies, Grand Island, NY,
USA) containing 10% FCS, 2mM glutamine (Sigma Chemical Co.,
St Louis, MO, USA), and penicillin/streptomycin (Invitrogen Life
Technologies, Melbourne, Victoria, Australia). The 806 antibody
shows negligible binding to these cells by FACS analysis (data not
shown).
Sequencing of murine 806 variable antibody regions
Total cytoplasmic RNA from the 806 hybridoma was obtained
using standard RNA isolation techniques (Chomczynski and
Sacchi, 1987). The first strand cDNA synthesis kit (Amersham
Pharmacia Biotech, Castle Hill, NSW, Australia) was employed to
generate the single strand cDNA. Control cDNA synthesis
reactions were carried out in the absence of reverse transcriptase.
PCR was carried out on 0.2pmolml
 1 of the cDNA template,
25pmolml
 1 primers in the presence of 2.5 units of Platinum Taq
DNA polymerase High Fidelity (Invitrogen Life Technologies,
Melbourne, Victoria, Australia) under standard conditions (60mM
Tris-SO4, pH 8.9, 18mM (NH4)2SO4,2m M MgSO4, 0.2mM of each
dNTP) in volumes of 50ml in MJ Research PTC200 thermocycler
(GeneWorks, SA, Australia). Primers for the amplification of heavy
and light chains were, in the case of 50-end primers, a compilation
based on the leader peptide sequence of known mouse antibodies
(Jones and Bendig, 1991). In regard to the 30-end primers, the
light-chain primer hybridised within the mouse kappa constant
region not too distant from the V–C junction. The heavy-chain
primer hybridised within the CHI constant region not far from the
V–CH1 junction. In all cases, 30 cycles of amplification were
carried out following the ‘hot-start’ using the following parameters:
denaturation for 1min, 941C; annealing 1min 45–651C; extension,
2min at 681C. A final 10-min extension step at 681C followed the
30 cycles. The PCR products were analysed by DNA electrophor-
esis, cloned using the TA Cloning System (Invitrogen Life
Technologies, Melbourne, Australia) then extensively sequenced.
Pseudogenes that were cloned during this procedure were
identified following sequencing and eliminated from the further
analysis. Novel VH and VL regions were identified for the 806
antibody and used in the subsequent chimerisation strategy.
Construction of a mouse–human chimeric 806 antibody
The ch806 antibody was designed to have the variable regions of
heavy and light chains of murine 806 linked to human gamma-1
and kappa constant regions, respectively. PCR primers used to
modify the 50- and 3
0
-sequences flanking the cDNA sequences
coding for the mouse 806 VL and VH regions incorporated Kozak
sequence (Kozak, 1987) and Pmel restriction enzyme site (for 50
primers), and splice donor site and BamHI restriction enzyme site
(for 30 primers). The sequences of the primers were as follows: VL
50-end primer AGCTTTGTTTAAACGCCGCCACCATGGTGTCCA
CAGCTCAGTTCC; VL 30-end primer CCGAGGATCCACTCACGTT
TGATTTCCAGCTTGGTGCC; VH 50-end primer AGCTTTGTTTAA
ACGCCGCCACCATGAGAGTGCTGATTCTTTTGTGG; VH 30-end
primer CCGAGGATCCACTCACCTGCAGAGACAGTGACCAGAGT.
The adapted amplified mouse 806 variable regions were subse-
quently subcloned into mammalian cell expression vectors already
Characterisation of the novel chimeric anti-EGFR antibody, ch806
C Panousis et al
1070
British Journal of Cancer (2005) 92(6), 1069–1077 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scontaining the human kappa (pREN-Neo vector) or gamma-1
(pREN-DHFR vector) constant regions. The vectors employ parts
of the human elongation factor promoter/enhancer sequence
(Mizushima and Nagata, 1990) to efficiently transcribe the light
and heavy chains, and provide high-level antibody production
via a mechanism of internal translation initiation in bicistronic
mRNA.
Expression of ch806 antibody in DHFR-deficient CHO
DG44 cells
DNA for transfections was purified from Escherichia coli cells
using Qiagen Plasmid Midi Kit (Qiagen, Clifton Hill, Victoria,
Australia) as recommended by the manufacturer. All DNA
preparations were examined by restriction enzyme digestion.
Sequencing of the 806 variable regions was performed at
MicroMon DNA Sequencing Facility (Department of Microbiology,
Monash University, Victoria, Australia). For transfection of the
DHFR-deficient CHO DG44 cells, plasmids encoding heavy and
light chains of the ch806 antibody (10mg circular plasmid for each
construct) were cotransfected into CHO DG44 cells growing at log
phase using electroporation (270V, 975mF; BioRad, Victoria,
Australia). Cells were plated in 10-cm dishes and cultured with
standard medium. After 24h, medium was replaced by fresh
IMDM medium supplemented with 10% dialysed FCS (Life
Technologies, Grand Island, NY), 500mg/ml Geneticin and 5nM
GMP-grade methotrexate (Life Technologies, Grand Island, NY,
USA). After the initial phase of cell killing was over (days 10–14),
outgrowing colonies were picked and screened for antibody
production. The best producing clones were then subjected to an
amplification procedure by increasing the methotrexate concen-
tration to 100nM and maintaining all other conditions. Outgrowing
colonies under these conditions were then picked, screened and
the highest producing clones taken for further analysis.
Analysis of ch806 binding activity
FACS and BIAcore binding specificity and affinity studies were
undertaken as described previously (Liu et al, 2003). Biacore
analyses utilised recombinant soluble extracellular domain of the
EGFR (sEGFR621) (Liu et al, 2003). For both studies, ch806 was
purified from cell culture supernatant using standard recombinant
Protein-A affinity and size exclusion chromatography purification.
Protein concentration was measured spectrophotometrically.
Analysis of ch806 immunological effector functions
Complement-dependent cytotoxicity (CDC) and antibody-depen-
dent cellular cytotoxicity (ADCC) of mAb 806, ch806 and isotype
control cG250 were undertaken as described previously (Scott et al,
2000) and utilised U87MG.de2-7 and A431 cells as target cells
(effector: target cell ratio¼50:1) over the antibody concentration
range 0.00315–10mgml
 1. Freshly isolated PBMC effector cells for
ADCC analyses and complement for the CDC assays was freshly
prepared from healthy donors as described previously (Scott et al,
2000).
Radiolabelling and quality assurance
Ch806 and isotype control antibody (huA33) were radiolabelled
either directly with iodine-125 (
125I) or via a bifunctional metal ion
chelating agent, CHX-A00-DTPA, for indium-111 (
111In) (Lee et al,
2001). Radioiodination with
125I (NEN Life Science Products,
Boston, MA, USA) was performed via a modified chloramine-T
reaction (Hunter and Greenwood, 1962), using a chloramine
T:protein ratio of 3:1 as previously described (Lee et al, 2001).
Antibody labelling with
111In was achieved via a bifunctional metal
ion chelating agent, CHX-A00-DTPA (Wu et al, 1997) as previously
described (Lee et al, 2001). Radiolabelling was performed on
the day of injection into mice. Prior to injection, percentage (%)
of unbound radionuclide content was determined by instant
thin layer chromatography (ITLC), and binding ability of the
final radiolabelled product was tested by a de2-7EGFR-positive
cell binding (Lindmo) assay as detailed below. Scatchard analysis
was used to determine the binding constant (Ka) and number of
antibody molecules bound per cell for
125I- and
111In-labelled
antibody.
Radiochemical purity
The amount of free vs bound antibody following radiolabelling
was determined by ITLC as previously described (Lee et al, 2001).
Assays were performed in duplicate. The percentage of isotope
bound to ch806 was 490% in all experiments detailed.
Immunoreactivity
The immunoreactive fraction of the radiolabelled constructs with
U87MG.de2-7 target cells was determined by linear extrapolation
to binding at infinite antigen excess using a ‘Lindmo’ assay
(Lindmo et al, 1984) as previously described (Lee et al, 2001).
Serum stability
Serum stability was assessed by incubating 5.0mg of each
radiolabelled protein in 200ml of healthy donor human serum at
371C for a 7-day period. Single-point immunoreactivity assays at
0 (no incubation), 4.0 and 7.0 days of incubation were undertaken.
Animal models
In vivo studies were performed in 5–6-week-old female athymic
BALB/c nude mice, homozygous for the nu/nu allele, bred by the
SPF Facility, University of South Australia. Mice were maintained
in autoclaved micro-isolator cages housed in a positive pressure
containment rack (Thoren Caging Systems Inc., Hazelton, PA,
USA). All animal studies were approved by the Austin Hospital
Animal Ethics Committee and were conducted in compliance with
NHMRC/CSIRO/AAC Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes.
To establish xenografts, mice were injected subcutaneously
into the left inguinal mammary line with 3 10
6 U87MG.de2-7
human glioma cells, or 5 10
6 A431 adenocarcinoma cells or
5 10
6 FaDu (HTB-43) control squamous cell carcinoma cells in
100ml of PBS. Tumour volume (TV) was calculated by the formula
[(length width
2)/2] (Clarke et al, 2000), where length was the
longest axis and width the measurement at right angles to length.
In an initial biodistribution experiment, 40 BALB/c nude mice
with established U87MG.de2-7 xenografts (mean7s.d. TV¼
380.47170.9mm
3) received radiolabelled
111In-ch806/
125I-ch806
(3mg, 10mCi
111In-CHX-A00-DTPA-ch806; 3mg, 3.8mCi
125I-ch806)
intravenously via the tail vein (total volume¼0.1ml). In a separate
study, groups of 12 mice with established A431 xenograft
(mean7s.d. TV¼99.3734.0mm
3) or established FaDu xenografts
(mean7s.d. TV¼134.8733.2mm
3) received radiolabelled
111ln-
ch806/
125I-ch806 (3.3mg, 7.5mCi
111In-CHX-A00-DTPA-ch806;
3.3mg, 3.8mCi
125I-ch806) intravenously via the tail vein (total
volume¼0.1ml). At designated time points after injection of the
radioconjugates (t¼4h, days 1, 2, 3, 5 and 7), groups of mice
(n¼3–5) were killed by Ethrane anaesthesia. Mice were then
exsanguinated by cardiac puncture, and tumours and organs (liver,
spleen, kidney, muscle, skin, bone (femur), lungs, heart, stomach,
brain, small bowel, tail and colon) were resected immediately. All
samples were counted in a dual gamma scintillation counter
(Packard Instruments). Triplicate standards prepared from the
injected material were counted at each time point with tissue and
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stumour samples enabling calculations to be corrected for the
physical decay of the isotopes. The tissue distribution data were
calculated as the mean7s.d. percent injected dose per gram tissue
(%IDg
 1) for the ch806 antibody per time point.
Pharmacokinetics
Serum obtained from mice bearing U87MG.de2-7 xenografts,
following infusion of radiolabelled-ch806 as described above, was
aliquoted in duplicate and counted in a gamma scintillation
counter (Packard Instruments, Melbourne, Australia). Triplicate
standards prepared from the injected material were counted at
each time point with serum samples to enable calculations to be
corrected for the isotope physical decay. The results of the serum
were expressed as % injected dose per litre (% IDl
 1).
Pharmacokinetic calculations were performed of serum data
using a curve fitting program (WinNonlin, Pharsight Co.,
Mountain View, CA, USA). A two-compartment model was used
to calculate serum pharmacokinetic parameters of AUC (area
under the serum concentration curve extrapolated to infinite
time), CL (total serum clearance), T1/2a and T1/2b (half-lives of
the initial and terminal phases of disposition) for
125I- and
111In-ch806.
Therapeutic in vivo studies
U87MG.de2-7 tumour cells (3 10
6) in 100ml of media were
inoculated subcutaneously (s.c.) into both flanks of 4–6-week-old
female nude mice (n¼5group
 1). Antibody treatment com-
menced day 7 post-tumour cell inoculations (mean7s.e. tumour
volume¼60715mm
3) and consisted of six intraperitoneal (i.p.)
injections over 2 weeks of 1mg ch806, 1mg murine 806, 1mg
murine 528 pan anti-EGFR antibody, or vehicle control. Tumour
volume in mm
3 was determined as described previously. Data were
expressed as mean tumour volume7s.e. for each treatment group.
Differences in tumour size between control and test groups were
tested for statistical significance (Po0.05) by t-test.
RESULTS
Engineering and expression of ch806
Chimeric 806 cDNA was initially engineered into expression
vectors where the antibody genes, and the genes used for resistance
to selection, were driven by CMV and SV40 promoters,
respectively. Using these expression vectors, a gradual decrease
in the production rates for ch806 by transfected CHO DG44 cells
was observed with increasing cell passage number. Northern
analysis of clones at various passage number revealed a loss of
mRNA for the expression of the heavy-chain antibody gene with
no loss in message levels for either the light-chain (neomycin) or
heavy-chain (DHFR) selectable markers, nor the light-chain
antibody gene (data not shown).
Based on these results, a next generation expression vector
system (pREN) was constructed with the engineering of an internal
ribosome entry site (IRES) between the antibody genes and the
selectable markers. In this system, antibody producing CHO DG44
clones cannot express the genes required for resistance to selection
without expression of the antibody genes. Using the pREN vectors,
all clones growing under selection conditions for light-chain
expression (G418) and heavy-chain expression (methotrexate)
were shown to stably produce ch806 over time.
Binding specificity and affinity
Ch806 was compared to its murine parental antibody for binding
specificity to a variety of cells expressing both mutant de2-7 EGFR
and overexpressed EGFR (Figure 1). These FACS results clearly
show that the ch806 antibody displays the identical binding
specificity as the murine parent. As previously reported for mAb
806 (Mishima et al, 2001; Johns et al, 2002) ch806 reacted
intensively with U87MG.de2-7 cells, less binding was observed
with A431 cells containing amplified EGFR, and weak binding with
U87MG.wtEGFRcells. BIAcore analysis with recombinant sEGFR
revealed the chimeric antibody to have retained the entire original
binding affinity of the murine parent (1.1 10
9 M
 1; data not
shown).
Immune effector functions
The results of the CDC analyses are presented in Figure 2A.
Minimal CDC activity was observed in the presence of up to
10mgml
 1 ch806 with CDC comparable to that observed with the
murine mAb 806 and isotype control cG250. Ch806-mediated
ADCC was determined at an E:T ratio of 50:1 on target A431
(Figure 2B) and U87MG.de2-7 cells (Figure 2C). In contrast to the
parental mAb 806 and isotype control antibodies, high-specific
cytotoxicity was observed with ch806 against target U87MG.de2-7
cells with 47% cytotoxicity effected by 0.03mgml
 1 ch806. Lower
ADCC was mediated by ch806 on A431 cells that contain lower
numbers of binding sites (Figure 2B).
Antibody radiolabelling
Radiochemical purity assessment of radiolabelled antibody by
ITLC prior to injection confirmed 498.6% bound
125I- (1.4% free)
and 499.3% bound
111In-CHX-A00-DTPA. The immunoreactivity
of
l25I-ch806 was 68.1% and
111In-ch806 was 69.5% for U87MG.
de2-7 cells. Ka values for
111In and
125I were 1.36 10
9 M
 1 and
1.90 10
9 M
 1, respectively, which is highly comparable to that
of the parental murine mAb806 of 1.1 10
9 M
 1 (Johns et al, 2002)
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Figure 1 FACS analysis of (A) A431 adenocarcinoma cell line (amplified
EGFR) and (B) parental and (C) transfected U87MG glioma cell lines stably
expressing wt (U87MG.wtEGFR) or (D) mutant EGFR (U87MG.de2-7).
Cells were incubated with mAb806 (–), ch806 (--) followed by Alexa488-
labelled anti-mouse Ig. The plots represent fluorescence intensity on the
abscissa and cell number per fluorescence channel on the ordinate. The
negative control (irrelevant antibody) fluorescence is plotted on each panel
(black line).
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sand the BIAcore determinations. The number of antibody
molecules bound per U87MG.de2-7 cell for each isotope were
6 10
5 for
111In, and 4.7 10
5 for
I25I.
Serum stability
In order to assess the potential stability of ch806 administered to
patients, serum stability studies were undertaken (Table 1). These
results demonstrate that in the presence of human serum at 371C
for up to 7 days incubation, ch806 shows excellent stability, as
measured by the radiochemical purity and percentage of antibody
binding to de2-7 EGFR-expressing cells in a single-point
immunoreactivity assay.
Biodistribution
The
125I/
111In-labelled biodistribution study results are presented
in Figures 3 and 4. The comparison of %IDg
 1 of
I25I- and
111In-
labelled ch806 in mice bearing U87MG.de2-7 xenografts are
detailed in Figure 3A and in mice bearing A431 tumours in
Figure 3B. The %IDg
 1 of
l25I-ch806 in U87MG.de2-7 tumours
peaked at 24h while the
111In-ch806 in U87MG.de2-7 xenografts
peaked at 48h following antibody injection with the uptake of
111In-labelled ch806 being four-fold greater than
I25I (mean: 30.7 vs
7.2% IDg
 1, respectively) and reaching statistical significance
(P¼o0.001). Uptake of ch806 within glioma xenografts was
superior for the
111In label at all time points studied, and of note
the
111In uptake was more than six-fold that of
125Ia tt¼72h to
312h inclusive (Figure 3A).
Despite only binding B10% EGFR on A431 cells the
111In-ch806
demonstrated a mean peak uptake at 3 days of 33%IDg
 1 and was
highly retained within the tumour over the study period, in
marked contrast to
125I-ch806, which showed minimal specific
A431 tumour uptake. A peak A431 tumour:blood ratio of 5:1 was
observed at day 7 for
111ln-ch806. No specific tumour uptake was
observed with either radioconjugate in the FaDu xenografts which
express normal tissue levels of EGFR (Figure 3C).
The biodistribution of radiolabelled ch806 in normal murine
tissues was studied, and results for time periods between 4 and
312h following injection of radiolabelled ch806 in mice bearing
U87MG.de2-7 xenografts are presented in Figure 4. Highly
comparable patterns of biodistribution in normal tissues were
observed in mice bearing A431 and FaDu xenografts (data not
shown). The %IDg
 1 in all normal tissues was less than 10%
except for the kidney and blood where initial activity was
consistent with blood pool of the radioconjugates.
Pharmacokinetics ch806
Calculation of pharmacokinetic parameters for ch806 are pre-
sented in Table 2. Similar times for initial and terminal phases of
disposition were observed of the
111In- and
125I-labelled ch806
conjugates, with the slightly slower clearance of
111In-ch806
attributing to a greater AUC for this conjugate.
Ch806 therapy of established tumour xenografts
The results of in vivo therapy experiment in BALB/c mice bearing
de2-7EGFR-positive xenografts are presented in Figure 5. Com-
pared to vehicle control, the murine mAb 806 significantly
inhibited the growth of U87MG.de2-7 gliomas by day 14
(Po0.05), and this growth inhibition remained significant up to
day 30 (P¼0.04). The pan anti-EGFR antibody 528 significantly
inhibited the growth of U87MG.de2-7 gliomas by day 14 (Po0.05);
however, this growth inhibition was significant only to day 23
(P¼0.023). Ch806 showed more significant growth inhibition by
day 10 (Po0.05), and tumour growth remained significantly
inhibited to day 30 (P¼0.001). Ch806 inhibition of tumour growth
was significantly greater than mAb 806 (P¼0.014) or 528
(P¼0.025) on day 30. There were 30% complete responders by
day 30 for ch806, and none for mAb806 or 528.
DISCUSSION
We report the successful engineering and expression of a chimeric
monoclonal antibody with specificity for the unique epitope bound
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Figure 2 Immune effector function of mAb 806 (J), chimeric IgGl antibody ch806 (K) and Isotype control cG250 (.). (A) Complement-dependent
cytotoxicity activity of 0–10mgml
 1 antibody on target U87MG.de2-7 cells. Antibody-dependent cellular cytotoxity on target (B) A431 cells and (C)
U87MG.de2-7 cells at effector-to-target cell ratio of 50:1 and antibody concentrations ranging from 0 to 10mgml
 1. Mean (bars;7s.d.) percent cytotoxicity
of triplicate determinations are presented. Representative results from three separate experiments are shown.
Table 1 Radiolabelled ch806 serum stability at 371C
Time (day) 0 4 7
111In-ch806 radio purity (%) 99.5 97.4 96.9
111In-ch806 IR (%) 69.5 63.7 66.7
125In-ch806 radio purity (%) 99.0 95.6 95.0
125In-ch806 IR (%) 68.1 62.2 63.2
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overexpressed EGFR (Luwor et al, 2001; Mishima et al, 2001;
Johns et al, 2002, 2004; Jungbluth et al, 2003). Ch806 was stably
expressed in CHO cells and exhibited antigen binding specificity
and affinity identical to that of its parent murine antibody. These
results are not unexpected since the antigen binding variable
regions are not altered in the chimeric version and remain murine
in origin. Much technological progress has been made in the last
decade on the generation of CDR-grafted humanised antibodies
and fully human antibodies in an attempt to remove the murine
nature of the variable region seen with chimeric antibodies (Clark,
2000). Often the humanisation process results in antibodies where
the antigen binding affinity is significantly lower than the murine
parent antibody. In our clinical experience, we have not seen
greater immunogenicity for chimeric antibodies compared to
humanised antibodies (Ritter et al, 2001; Scott et al, 2001, 2003). In
fact, taken together with the cost of generating a humanised
antibody (including intellectual property and time for generation)
and the often impaired antigen binding activity, we believe
chimeric antibodies are a suitable format for translation of a
murine antibody with potential into a human product candidate.
This is reflected in the scope of chimeric monoclonal antibodies in
the clinic, and the FDA’s approval for ReoPro
s (abciximab),
Rituxan
s (rituximab), Remicade
s (infliximab), Simulect
s (basi-
liximab) and Erbitux
s (cetuximab).
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Figure 3 The biodistribution over 7 days of
111In-CHX-A00-DTPA- and
125I-labelled ch806 in (A) U87MG.de2-7 xenografts, (B) A431 xenografts, (C)
FaDu xenografts and serum from BALB/c nude mice. Results are expressed as mean (bars; 7s.d.) percent injected dose per gram (%IDg
 1) for each time
point, (n¼3–5 mice). The data are presented as:
111In-serum (’);
111In-tumour (m),
125I-serum (K), and
125I-tumour (.).
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Figure 4 Normal tissue biodistribution of radiolabelled ch806 over 7
days in BALB/c nude mice bearing tumour xenografts (n¼5). Results of the
biodistribution of (A)
111In-CHX-A00-DTPA-ch806 and (B)
125I-ch806 are
presented for each tissue expressed as mean (bars;7s.d.) percent injected
dose per gram (%IDg
 1) values.
Table 2 Pharmacokinetic parameters for radiolabelled ch806 in serum
and tumour (mean7s.e.)
T1/2a (h) T1/2b (hr) AUC (hlgml
 1)C L( m l h
 1)
Serum
111In-ch806 3.4270.92 78.64715.40 66.7977.94 0.04570.005
Serum
125I-ch806 2.8570.24 69.8776.56 47.5272.61 0.06370.003
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Figure 5 Antitumour effect of ch806 on U87MG.de2-7 glioma
xenograft growth rates. U87MG.de2-7 cells (3 10
6) were injected s.c.
into both flanks of 4–6-week-old BALB/c nude mice at day 0. Antibody
treatment commenced on day 7 post-tumour-cell inoculation and
consisted of six i.p. injections over 2 weeks of 1mg ch806 (m), 1mg
mAb 806 (K), 1mg 528 anti-EGFR (.), or vehicle control (’) on days 7,
9, 11, 14, 16 and 18 (arrows). Mean tumour volume (bars;7s.e.) for each
treatment group (n¼5) is presented. *P¼0.04, mAb 806 vs control, day
30. **P¼0.001, ch806 vs control, day 30. ***P¼0.014, ch806 vs mAb
806, day 30; P¼0.025, ch806 vs 528, day 30.
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function, the chimerisation process led to an antibody with strong
ADCC activity. Interestingly, there was no concurrent increase in
CDC activity. This immune effector function profile for chimeric
antibodies generated in DG44 cell has been observed with a
number of antibodies generated within our laboratory (Panousis,
personal communication). It is possible that the glycosylation
profile of CHO-cell-derived antibodies impairs or prevents the
binding of Clq and consequent activation of the classical
complement pathway (White et al, 1997). This phenomenon is
being explored further in our laboratory. The levels of ADCC
achieved with the two different target cell lines reflected the
number of ch806 binding sites on the two cell populations. Ch806
targets B1 10
6 de2-7EGFR on U87MG.de2-7 cells effecting
greater ADCC compared to A431 cells where only a subset of the
2 10
6 wt EGFR molecules are recognised by ch806 (Luwor et al,
2001; Johns et al, 2002). The strong ADCC activity displayed by
ch806 compared to the murine antibody (which lacks significant
ADCC) has provided a further tumour cell killing mechanism to
enhance the direct signalling-mediated killing activity displayed by
ch806.
We have examined the in vivo biodistribution, pharmacoki-
netics and labelling stability of ch806.
125I- and
111In-conjugated
ch806 retained binding affinity to de2-7EGFR-expressing glioma
cells and were also stable in vitro as assessed by ITLC. The binding
affinity of ch806 was retained, despite prolonged incubation at
371C in serum and during in vivo animal experiments. Pharma-
cokinetic and biodistribution studies in BALB/c nude mice
demonstrated a long serum half-life and excellent and specific
targeting properties for tumours containing de2-7EGFR or
amplified EGFR. The prolonged and superior tumour uptake
observed for
111In-ch806 compared to the
l25I-conjugate suggest
that ch806 is rapidly internalised following binding with con-
comitant catabolism and excretion of the radiohalide from the
tumour cell. Other xenograft studies with internalising antibodies
have also demonstrated lower absolute levels of iodine uptake
compared with
111In (Clarke et al, 2000). The differences in tumour
retention of radiolabel in this study most likely represents
differences in cellular processing of radiolabelled
I25I as opposed
to
111In. The current observation is consistent with the rapid
internalisation characteristics of mAb 806 observed in confocal
and EM experiments with de2-7 and amplified EGFR-expressing
cell lines (Johns et al, 2002). The need to utilise
111In to visualise
antibody tumour localisation raises the issue of how many
antibodies have been prematurely aborted from further develop-
ment based on initial results from biodistribution studies under-
taken using radio-iodine-labelling and suggests that negative
results obtained thusly should always be confirmed with a
radiometal-based nuclide.
The ability of ch806 to inhibit the growth of de2-7-expressing
tumour xenografts in BALB/c mice was compared to the murine
parent antibody and the anti-EGFR antibody 528. While mAb 806
demonstrated similar tumour growth inhibition to 528, the results
clearly show that the chimerisation process has improved the
ability of ch806 to impair significantly the growth of tumour
xenografts in vivo. A direct killing mechanism impacting on
cellular signalling mechanisms required for tumour cell prolifera-
tion remains a major factor in the likely mode of action for ch806;
however, some immunological function using murine effector cells
(ADCC) may also account for the improved efficacy of ch806 over
mAb 806. Mechanisms associated with the anti-tumour activity of
ch806 are under further investigation in our laboratory.
The overexpression of EGFR in many types of epithelial cancers
EGFR renders it an attractive target for tumour-targeted antibody
therapy. A number of EGFR antibodies have been reported in the
literature with several undergoing clinical evaluation. (Arteaga,
2002; Herbst and Langer, 2002) and more recently the chimeric
antibody C225 (Erbitux
s) was approved for use with irinotecan in
advanced colon cancer. The antitumour activity of most EGFR
antibodies, including the codeveloped 225 and 528, is enhanced by
their ability to block ligand binding (Arteaga, 2002; Herbst and
Langer, 2002). Such antibodies may mediate their efficacy through
both modulation of cellular proliferation and antibody-dependent
immune functions (e.g. complement activation). The mAb 806 was
generated following immunisation with mouse fibroblasts expres-
sing the de2-7 EGFR and was selected by mixed haemadsorption
assay for high reactivity to de2-7 EGFR and negligible activity
against the wt EGFR (Jungbluth et al, 2003). Further characterisa-
tion revealed that mAb 806 could recognise cell lines and glioma
specimens when the wt EGFR was overexpressed, especially when
the EGFR gene was amplified, but not normal tissue (Johns et al,
2002). Our recent observation that mAb 806 binds an epitope
revealed by the de2-7 EGFR truncation that is also exposed by the
untethered EGFR, suggests that 806 prevents the formation of
signalling-capable EGFR (Johns et al, 2004). The chimerisation of
806 has markedly improved the ADCC effected by this antibody
and the in vivo characteristics of this antibody show great promise
for clinical studies.
In conclusion, we have generated a chimeric antibody with
specificity for the de2-7 EGFR and amplified EGFR, but not normal
tissue, by targeting a novel epitope that is only transiently exposed.
The tumour-restricted expression and cell surface location of the
806 antigen make it an ideal target for immunotherapeutic
strategies utilising ch806 with exciting clinical potential against a
variety of human epithelial tumours including head and neck
tumours and glioma. In contrast to other anti-EGFR antibodies in
clinical development or approved by the FDA (e.g. Erbitux
s) that
also bind normal EGFR present on normal human skin and liver,
ch806 is a novel direct-killing anticancer antibody with specificity
only for the tumour it is targeting, and not normal human cells.
This provides opportunities for naked antibody therapy, radio-
immunotherapy and the use of ch806-based drug immunoconju-
gates, where a cytotoxic agent could be used to target the tumour
and possibly work synergistically with the direct killing mechan-
isms of ch806, yet sparing toxicity to normal cells. The in vitro
characteristics and stability of ch806 together with the in vivo
biodistribution and antitumour data indicate properties that are
suited for translation to the clinic in Phase I trials.
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